Company / Working Capital
Supernus Pharmaceuticals, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$306.0M
FY2025
5-year range
$46.2M / $393.7M
FY2021-FY2025
Trend
-22.3%
vs FY2024
Sector context
#137 of 213
Health Care
What the data says
At $306M, Supernus Pharmaceuticals, Inc.'s working capital ranks #137 of 213 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $46M in FY2022 to $394M in FY2024.
Based on SEC 10-K filings.
$306M in FY2025 with a 5-year CAGR of -4.5%.
Improved from $203M to $306M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +87.8%
- 5-Year CAGR
- -4.5%
- 10-Year CAGR
- -
Sector benchmark
#137 of 213 in Health CareTop 64% of 213This company $306.0M Sector average $934.6M
▼
-67.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.5%, indicating a declining trend.
- In FY2025, working capital decreased 22.3% year-over-year.
- Ranks #137 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $306.0M | -22.3% |
| FY2024 | $393.7M | +94.0% |
| FY2023 | $202.9M | +339.3% |
| FY2022 | $46.2M | -83.9% |
| FY2021 | $286.2M | -25.7% |
| FY2020 | $385.3M | +23.5% |
| FY2019 | $312.1M | -6.0% |
| FY2018 | $332.1M | +215.0% |
| FY2017 | $105.5M | +49.2% |
| FY2016 | $70.7M | +44.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026